To further validate our in vitro analyses of DVL2 role in HER2+ breast cancer, we performed TIL-scoring and mapped DVL2 and CD8α protein levels via immune staining in a preliminary sample of 24 HER2+ breast cancer patients at baseline biopsy (N = 24) and post NAC resection (N = 14) tissues. This evidence concerns the gene CD8A and breast cancer.